NCT00289562View on ClinicalTrials.gov

Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic Leukemia

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions
B-cell Acute Lymphoblastic Leukemia
Interventions
DRUG

forodesine hydrochloride (BCX-1777)

Trial Locations (7)

10021

New York

10029

New York

24211

Abingdon

60637

Chicago

66160

Kansas City

77030

Houston

80218

Denver

Sponsors
All Listed Sponsors
lead

BioCryst Pharmaceuticals

INDUSTRY